,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,12 Penns Trail,Newtown,PA,18940,United States,267 759 3680,267 759 3681,https://www.onconova.com,Biotechnology,Healthcare,"Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.",16,"{'maxAge': 1, 'name': 'Dr. Steven M. Fruchtman M.D.', 'age': 71, 'title': 'CEO, Pres & Director', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 907859, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7751,0.77,0.77,0.8099,0.7751,0.77,0.77,0.8099,0.0,1.765905,-0.5999259,75386,75386,58609,40170,40170,0.78,0.846,2900,900,16989758,0.62,1.49,75.17592,0.934,0.93665,0.0,0.0,USD,-12739222,0.0,20823020,20977600,64089,105439,1690761600,1693440000,0.0031,0.0055,0.06807,1.22,0.0031,0.901,0.8988901,1672444800,1703980800,1688083200,-20843000,-1.04,-1.35,1:15,1621555200,-56.368,0.576,NCM,EQUITY,ONTX,ONTX,"Onconova Therapeutics, Inc.","Onconova Therapeutics, Inc.",1374759000,America/New_York,EDT,-14400000,0.8099,11.0,5.0,7.5,7.0,1.5,strong_buy,4,29729000,1.417,-22108000,0,3.432,3.514,226000,0.011,-0.35207,-0.72646004,226000,-9583250,-16817000,0.0,1.0,0.0,-97.884964,USD,
1,12 Penns Trail,Newtown,PA,18940,United States,267 759 3680,267 759 3681,https://www.onconova.com,Biotechnology,Healthcare,"Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.",16,"{'maxAge': 1, 'name': 'Mr. Mark Patrick Guerin CPA', 'age': 53, 'title': 'CFO & COO', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 629267, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7751,0.77,0.77,0.8099,0.7751,0.77,0.77,0.8099,0.0,1.765905,-0.5999259,75386,75386,58609,40170,40170,0.78,0.846,2900,900,16989758,0.62,1.49,75.17592,0.934,0.93665,0.0,0.0,USD,-12739222,0.0,20823020,20977600,64089,105439,1690761600,1693440000,0.0031,0.0055,0.06807,1.22,0.0031,0.901,0.8988901,1672444800,1703980800,1688083200,-20843000,-1.04,-1.35,1:15,1621555200,-56.368,0.576,NCM,EQUITY,ONTX,ONTX,"Onconova Therapeutics, Inc.","Onconova Therapeutics, Inc.",1374759000,America/New_York,EDT,-14400000,0.8099,11.0,5.0,7.5,7.0,1.5,strong_buy,4,29729000,1.417,-22108000,0,3.432,3.514,226000,0.011,-0.35207,-0.72646004,226000,-9583250,-16817000,0.0,1.0,0.0,-97.884964,USD,
2,12 Penns Trail,Newtown,PA,18940,United States,267 759 3680,267 759 3681,https://www.onconova.com,Biotechnology,Healthcare,"Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.",16,"{'maxAge': 1, 'name': 'Dr. Adar  Makovski Silverstein Ph.D.', 'title': 'Sr. Director & Head of Corp. Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7751,0.77,0.77,0.8099,0.7751,0.77,0.77,0.8099,0.0,1.765905,-0.5999259,75386,75386,58609,40170,40170,0.78,0.846,2900,900,16989758,0.62,1.49,75.17592,0.934,0.93665,0.0,0.0,USD,-12739222,0.0,20823020,20977600,64089,105439,1690761600,1693440000,0.0031,0.0055,0.06807,1.22,0.0031,0.901,0.8988901,1672444800,1703980800,1688083200,-20843000,-1.04,-1.35,1:15,1621555200,-56.368,0.576,NCM,EQUITY,ONTX,ONTX,"Onconova Therapeutics, Inc.","Onconova Therapeutics, Inc.",1374759000,America/New_York,EDT,-14400000,0.8099,11.0,5.0,7.5,7.0,1.5,strong_buy,4,29729000,1.417,-22108000,0,3.432,3.514,226000,0.011,-0.35207,-0.72646004,226000,-9583250,-16817000,0.0,1.0,0.0,-97.884964,USD,
3,12 Penns Trail,Newtown,PA,18940,United States,267 759 3680,267 759 3681,https://www.onconova.com,Biotechnology,Healthcare,"Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.",16,"{'maxAge': 1, 'name': 'Dr. Victor  Moyo M.D.', 'title': 'Consulting Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7751,0.77,0.77,0.8099,0.7751,0.77,0.77,0.8099,0.0,1.765905,-0.5999259,75386,75386,58609,40170,40170,0.78,0.846,2900,900,16989758,0.62,1.49,75.17592,0.934,0.93665,0.0,0.0,USD,-12739222,0.0,20823020,20977600,64089,105439,1690761600,1693440000,0.0031,0.0055,0.06807,1.22,0.0031,0.901,0.8988901,1672444800,1703980800,1688083200,-20843000,-1.04,-1.35,1:15,1621555200,-56.368,0.576,NCM,EQUITY,ONTX,ONTX,"Onconova Therapeutics, Inc.","Onconova Therapeutics, Inc.",1374759000,America/New_York,EDT,-14400000,0.8099,11.0,5.0,7.5,7.0,1.5,strong_buy,4,29729000,1.417,-22108000,0,3.432,3.514,226000,0.011,-0.35207,-0.72646004,226000,-9583250,-16817000,0.0,1.0,0.0,-97.884964,USD,
